TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27095446
Drug: Oral fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fat load test meal (OFTT)
Study: 24767004
Drug: Cognitive control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive control therapy (CCT) + active transcranial direct current stimulation (tDCS)
Study: 24767004
Drug: Cognitive control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive control therapy (CCT)
Study: 21805294
Drug: Celastrus orbiculatus
Normalized name: Lotus corniculatus flower volatile oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celastrus orbiculatus extract (COE) at concentrations of 10, 20, 40, 80, and 160 μg/mL
Study: 17443478
Drug: Dose modifications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose modifications for nonhematologic toxicity
Study: 9604941
Drug: No Aspirin
Normalized name: XS No Aspirin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Aspirin
Study: 15309001
Drug: Withheld Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Withheld Aspirin
Study: 12040470
Drug: G-CSF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (5 microg/kg starting on the day of infusion)
Study: 12040470
Drug: G-CSF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (5 microg/kg starting five days later)
Study: 12040470
Drug: No G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No G-CSF (Control Group)
Study: 12040470
Drug: G-CSF (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (both arms A and B)
Study: 12040470
Drug: G-CSF on
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF on day 0 vs day +5
Study: 9408713
Drug: Clinical trials
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical trials of pharmacologic agents
Study: 3555036
Drug: Ciprofloxacin therapy
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin therapy (750 to 2,250 mg daily, mean 1,800 mg)
Study: 3555036
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (tobramycin or azlocillin)
Study: 31181990
Drug: Immediate Release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate Release (IR) formulation of cilostazol
Study: 31181990
Drug: Sustained Release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained Release (SR) formulation of cilostazol
Study: 23906190
Drug: Tamsulosin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.4 mg) from 1 day before to 14 days after surgery
Study: 23906190
Drug: No tamsulosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No tamsulosin treatment (control group)
Study: 23906190
Drug: Tamsulosin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin treatment
Study: 23906190
Drug: Tamsulosin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin treatment and control
Study: 23697477
Drug: Pharmaceutical counseling
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical counseling of hospital medical staff and additional information in the discharge letter for the PCP
Study: 20977584
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg LC15-0444
Study: 20977584
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg LC15-0444
Study: 20977584
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg LC15-0444
Study: 20977584
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of LC15-0444
Study: 18940296
Drug: Group-based high-intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based high-intensity aerobic interval training (exercise group, n = 40), exercised twice a week for 4 months plus 4 consultations with a CHF nurse.
Study: 12641613
Drug: Spatone Iron‐Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spatone Iron‐Plus (48 ml)
Study: 10595595
Drug: UL-TG 307
Approvals — FDA: no, EMA: no, PMDA: no
Description: UL-TG 307 (24 mg daily)
Study: 25052785
Drug: In-prison substance
Normalized name: poison ivy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-prison substance use and depression treatments
Study: 21928226
Drug: Prolonged prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prolonged prednisolone therapy (5-month)
Study: 15222602
Drug: Therapeutic touch
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic touch treatments (6 sessions)
Study: 11755284
Drug: Medical food
Normalized name: Medical food
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical food bar enriched with L-arginine and other nutrients
Study: 9842980
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of cisapride (10 mg per unit, 20 mg total dose)
Study: 9842980
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of cisapride (10 mg per unit, 20 mg total dose)
Study: 2947953
Drug: 10 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms hepatitis B vaccine
Study: 7856298
Drug: Both dosages
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosages of hepatitis B vaccine
Study: 30730866
Drug: Parecoxib sodium
Normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib sodium (40 mg) combined with TAP block (150 mg of 0.375% ropivacaine with 5 mg dexamethasone)
Study: 30730866
Drug: Placebo (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (40 mg) without TAP block
Study: 25504506
Drug: Arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Arsenic trioxide transarterial chemoembolization and intravenous administration of arsenic trioxide
Study: 20921922
Drug: Methylprednisolone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (30 mg/kg intravenously) administered at anesthetic induction
Study: 19318461
Drug: Increasing anticholinergic
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing anticholinergic load from symptom-specific medications
Study: 16505800
Drug: Bio-adhesive 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio-adhesive 0.2% chlorhexidine gel applied once after extraction
Study: 16505800
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no chlorhexidine gel)
Study: 16505800
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (chlorhexidine gel)
Study: 11414873
Drug: Staff-implemented treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staff-implemented treatments designed to experimentally increase intentional communication ability
Study: 8302763
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg oral dose of fadrozole hydrochloride
Study: 8302763
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg oral dose of fadrozole hydrochloride
Study: 8302763
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg oral dose of fadrozole hydrochloride
Study: 7833101
Drug: Fadrozole hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Fadrozole (DB16832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fadrozole hydrochloride (all doses)
Study: 31550915
Drug: 300,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300,000 IU of intramuscular vitamin D
Study: 27775998
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg methylprednisolone at induction and 250 mg methylprednisolone before cardiopulmonary bypass
Study: 26247968
Drug: Chia oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chia oil (16 mL daily) from the third trimester of pregnancy until the first six months of nursing
Study: 23438946
Drug: Tacrolimus (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus (5 mg) in CYP3A5 expressers
Study: 21527202
Drug: 1% testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% testosterone propionate ointment twice daily for 30 days before surgery
Study: 19623047
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose levels < or =1.2 mmol/L
Study: 16418786
Drug: Oral alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alendronate (10 mg daily)
Study: 15054349
Drug: 8.4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8.4 g/day larch arabinogalactan (n=18)
Study: 15054349
Drug: 8.4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8.4 g/day tamarack arabinogalactan (n=19)
Study: 11198705
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of intramuscular thiamin
Study: 11198705
Drug: Other doses
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other doses of intramuscular thiamin
Study: 3139325
Drug: 3,000 units
Normalized name: Ocrevus Zunovo, ocsq 23,000 units-920 mg /23 mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3,000 units pro‐urokinase i.c. (group L)
Study: 26312597
Drug: Teriparatide therapy
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide therapy
Study: 18784609
Drug: Maca (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maca (3.5 g/day for 6 weeks)
Study: 16651830
Drug: Test drug
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug (T) - oral desmopressin acetate 400 mug
Study: 9683118
Drug: Investigational interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Investigational interleukin-2 (IL-2) therapy
Study: 9160569
Drug: Brofaromine (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brofaromine (a combined MAO‐A inhibitor/5‐HT transport inhibitor)
Study: 11498312
Drug: Saline at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline at a rate of 2 mL/min (control group)
Study: 9921700
Drug: SSRI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRI plus buspirone (open-label poststudy treatment)
Study: 7519866
Drug: Moclobemide (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (various doses)
Study: 2667326
Drug: Interferon alternating
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alternating with chemotherapy (5-fluorouracil, doxorubicin, mitomycin, and cis-platin)
Study: 2667326
Drug: Chemotherapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy only (5-fluorouracil, doxorubicin, mitomycin, and cis-platin)
Study: 2667326
Drug: Interferon alternating
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alternating with chemotherapy
Study: 2667326
Drug: Both arms
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both arms (Interferon alternating with chemotherapy and Chemotherapy only)
Study: 31221891
Drug: Clinical decision
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical decision support system (CDSS) for detection of paediatric SIRS; specific dosage and duration not mentioned.
Study: 31221891
Drug: Routine clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine clinical care decisions; specific dosage and duration not mentioned.
Study: 26323728
Drug: Dexmedetomidine 0.5μg/kg/10min
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5μg/kg/10min infusion
Study: 26323728
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline infusion (Control Group)
Study: 23145864
Drug: Lacrimal probing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacrimal probing and irrigation with adjunctive mitomycin-C (1 mL of 0.2 mg/mL, once)
Study: 19635606
Drug: Recombinant interferon-alpha2b
Normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon-alpha2b (IFN) as an adjuvant to HBV vaccine
Study: 11146393
Drug: HBV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV vaccine alone
Study: 17111013
Drug: Carbohydrate supplementation
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate supplementation (1 g.kg body mass(‐1))
Study: 16900304
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment (ACT, social skills training, and family intervention)
Study: 11815428
Drug: Fosinopril 40
Normalized name: fosinopril 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril 40 mg
Study: 11329095
Drug: Fosinopril 1
Normalized name: fosinopril 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril 1 mg
Study: 11329095
Drug: Fosinopril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril (20 mg and 40 mg)
Study: 2191878
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g acetylsalicylic acid (ASA) per day, starting day two prior to surgery
Study: 2191878
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without antiplatelet medication
Study: 2191878
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g acetylsalicylic acid (ASA) in patients with signs of progression in histopathological examination
Study: 76397
Drug: Zinc sulphate
Normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulphate tablets, 0.6 g daily for 4 weeks
Study: 25251189
Drug: High COHb
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High COHb (≥4 g·dl(‐1))
Study: 25251189
Drug: Low COHb
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low COHb (≤3 g·dl(‐1))
Study: 16409323
Drug: sterile saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile saline solution + Hybrid technique
Study: 16409323
Drug: sterile saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile saline solution + NiTi rotary technique 4 mm shorter than the apex
Study: 16409323
Drug: sterile saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile saline solution + NiTi rotary technique (Hero 642)
Study: 9489432
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (NED) 8mg twice daily
Study: 8384073
Drug: Low-dose craniospinal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose craniospinal radiation therapy (1800 cGy) plus chemotherapy (vincristine during RT, followed by vincristine, cisplatin, and lomustine for eight cycles every 6 weeks)
Study: 8384073
Drug: Low-dose craniospinal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose craniospinal radiation therapy (1800 cGy) plus chemotherapy
Study: 2936841
Drug: Oral instruction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral instruction from physician and clinical nurse specialist
Study: 29115703
Drug: Sertraline (SRT)
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline (SRT) at 200 mg
Study: 25709987
Drug: Granisetron 3
Normalized name: granisetron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 3 mg iv 2 minutes before induction of anesthesia
Study: 25709987
Drug: Oral gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral gabapentin 300 mg 1 hour before anesthesia
Study: 21415104
Drug: Selenium (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium (500 μg/day)
Study: 21415104
Drug: Glutamine (20.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (20.2 g/day)
Study: 12752541
Drug: Mandibular implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular implant overdentures (IOD)
Study: 11922148
Drug: Diet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet and oral hypoglycaemic drug (Daonil) therapy
Study: 9725753
Drug: Halcion (triazolam)
Normalized name: triazolam Oral Tablet [Halcion]
DrugBank: Triazolam (DB00897)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Halcion (triazolam) 0.375 mg p.o.
Study: 31242139
Drug: Contrast water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast water therapy
Study: 21309657
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 to 324 mg per day)
Study: 2064065
Drug: Lumbar epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar epidural morphine 5 mg
Study: 2064065
Drug: Lumbar epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar epidural nalbuphine 10 mg
Study: 2064065
Drug: Lumbar epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar epidural nalbuphine 20 mg
Study: 6321426
Drug: Imipenem with
Normalized name: Imipenem
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Imipenem with cilastatin, 500 mg/500 mg iv tid
Study: 6321426
Drug: Cefotaxime, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime, 2 g iv tid
Study: 30564847
Drug: Paravertebral block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paravertebral block (Pv, n=20) with 20 ml 0.25% bupivacaine at the level of T8-T9
Study: 30564847
Drug: Peritubal infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritubal infiltration (Pi, n=20) with 20 ml 0.25% bupivacaine along the nephrostomy tube
Study: 30339623
Drug: Patch repair
Normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch repair (PROCEED Ventral Patch)
Study: 22926233
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg/d
Study: 23380218
Drug: Fluticasone 250
Normalized name: FLUTICASONE 250MCG/BLSTR PO INH ROTADISK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone 250 μg twice daily
Study: 15619331
Drug: Tailor-made treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailor-made treatment program addressing biopsychosocial factors
Study: 10620554
Drug: Recombinant tissue
Normalized name: Tissue plasminogen activator, recombinant
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant tissue plasminogen activator (rTPA) 2 mg
Study: 10620554
Drug: Heparin 2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 2,000 IU
Study: 8648870
Drug: Tricyclic antidepressants
Normalized name: TRICYCLIC ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic antidepressants (imipramine or desipramine)
Study: 8648870
Drug: Fluoxetine, Tricyclic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine, Tricyclic antidepressants
Study: 1335647
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine (720 ELISA units)
Study: 1335647
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (20 micrograms)
Study: 1335647
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of hepatitis A and B vaccines
Study: 6100260
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg dose)
Study: 6100260
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no drug administration)
Study: 3033966
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine (30 mg slow-release preparation)
Study: 3033966
Drug: Naloxone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (4 mg bolus iv)
Study: 3033966
Drug: Naloxone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (4 mg iv bolus followed by continuous infusion of 6 mg over 75 min)
Study: 3033966
Drug: Placebo (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (for both morphine and naloxone protocols)
Study: 25622666
Drug: 270 mgI/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 270 mgI/ml low concentrations of contrast agents and spectral CT imaging (Group A)
Study: 25622666
Drug: 350 mgI/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mgI/ml high concentrations of contrast agents and 120 kVp scan (Group B)
Study: 18721899
Drug: High-dose fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fish oil (9600 mg of fish oil/day, 2880 mg of n-3 fatty acids)
Study: 14576512
Drug: hANP (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: hANP (initial dose: 0.025 microg/kg/min, maximum dose: 0.035 +/- 0.019 microg/kg/min)
Study: 14576512
Drug: Control (nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (nicardipine hydrochloride; 4.41 +/- 1.68 mg/h)
Study: 8677571
Drug: Neoadjuvant MVAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant MVAC chemotherapy
Study: 8677571
Drug: Adjuvant MVAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant MVAC chemotherapy
Study: 2233115
Drug: Diltiazem 90
Normalized name: diltiazem 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 90 mg twice daily